IDEXX Laboratories, Inc. $IDXX Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. reduced its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 22.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 673,228 shares of the company’s stock after selling 196,702 shares during the quarter. JPMorgan Chase & Co. owned 0.84% of IDEXX Laboratories worth $455,460,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in IDXX. Empowered Funds LLC increased its position in IDEXX Laboratories by 6.6% in the 1st quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock valued at $646,000 after acquiring an additional 95 shares during the period. Sivia Capital Partners LLC acquired a new stake in IDEXX Laboratories in the 2nd quarter valued at approximately $265,000. Jump Financial LLC increased its position in IDEXX Laboratories by 1,006.4% in the 2nd quarter. Jump Financial LLC now owns 5,532 shares of the company’s stock valued at $2,967,000 after acquiring an additional 5,032 shares during the period. Cary Street Partners Financial LLC acquired a new stake in IDEXX Laboratories in the 2nd quarter valued at approximately $164,000. Finally, Sei Investments Co. increased its position in IDEXX Laboratories by 218.7% in the 2nd quarter. Sei Investments Co. now owns 120,587 shares of the company’s stock valued at $64,678,000 after acquiring an additional 82,755 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts recently commented on the company. UBS Group lowered their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. Stifel Nicolaus lowered their target price on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Weiss Ratings cut IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Citigroup started coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price on the stock. Finally, Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Seven research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Stock Performance

Shares of NASDAQ IDXX opened at $556.94 on Thursday. The stock has a fifty day moving average price of $563.22 and a two-hundred day moving average price of $629.35. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. The firm has a market cap of $43.93 billion, a P/E ratio of 41.01, a PEG ratio of 3.17 and a beta of 1.55. IDEXX Laboratories, Inc. has a 1 year low of $506.91 and a 1 year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. The firm had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The firm’s quarterly revenue was up 14.3% on a year-over-year basis. During the same period last year, the company posted $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Research analysts forecast that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.